Key Highlights

  • Accendra shares are trading down 0.47% at $0.25, with Volume near 32.65 million shares.
  • Receivables Sale Program now runs to October 2029, with its $150 million size unchanged.
  • Amendment was executed on Oct. 29, 2026 with the company's banking partner.

Accendra Health (NYSE:ACH) shares are trading down 0.47% at $0.25, in line with the previous close, after the company announced an extension of its $150 million Receivables Sale Program to 2029. Shares trade below $5, which makes the stock a penny stock, and volume is heavy at about 32.65 million shares.

Accendra Health, formerly Owens & Minor and based in Glen Allen, Virginia, provides products, technology and services that support home-based care through its Apria and Byram Healthcare brands. Following the sale of its legacy Products & Healthcare Services business, it has become a pure-play home care platform serving patients, providers and payors across diabetes, sleep apnea, respiratory therapy, wound care, ostomy, urology and incontinence.

Terms of the Amendment

Accendra executed an amendment to its Receivables Purchase Agreement on Oct. 29, 2026. The amendment extends the Scheduled Termination Date of the Facility to October 2029, and the size of the program remains $150 million.

Accendra has about 6,500 employees and operates a Business that bills a mix of payors, which makes steady access to short-term funding useful for day-to-day operations.

The company's chief financial officer said the company was pleased to have worked with its banking partner to extend the program. He said the unchanged facility size further ensures the company's Liquidity strength and demonstrates the strength of its Accounts Receivable portfolio and processes.

How a Receivables Sale Program Helps

A receivables sale program lets a company turn trade receivables into cash from a bank sooner than waiting for customers and payors to pay. For a home care provider that bills many payors, that can smooth Working Capital and reduce reliance on other forms of borrowing. A longer termination date also gives the business more visibility on one source of funding for the next three years.

The release does not provide pricing, fees or the amount drawn under the facility, so the extension changes the length of the arrangement but not its stated capacity.

Stock Context and What to Watch

The shares sit far below their 52-week high of $4.69 and close to the low of $0.19, which leaves the stock about 95% under the top of its range. The move is a small one, and the extension is a funding update rather than a change in operating results.

Investors will watch how the company performs as a stand-alone home care business after the divestiture, including cost savings, cash generation and indebtedness. The release states that its forward-looking comments cover its 2026 financial results, cost saving initiatives, future indebtedness and growth. Updates on those measures, and on how heavily the company uses the receivables facility, will matter more for the stock than the extension itself.